April 12, 2013 5:58 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Otsuka Pharmaceutical Co (OTC: OTSKY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company's new drug application (NDA) for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Phase III clinical trial results that form the basis of the regulatory filing were published online in the New England Journal of Medicine.1 ADPKD is a hereditary genetic illness characterized by the development of multiple cysts in the kidneys. ADPKD is the most common inherited kidney disease and the fourth most common overall cause of kidney failure worldwide, with the diagnosed prevalence estimated to be between 1:1,000 and 1:4,000 globally.
See full press release
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.